BRISBANE, Calif.--(BUSINESS WIRE)--Tercica, Inc. (Nasdaq:TRCA) today announced that the Company has completed enrollment of its MS308 Phase 3b clinical trial, which is a study evaluating the efficacy and safety of the currently approved formulation of Increlex® administered as a once-daily injection in children with Primary IGF-1 Deficiency (Primary IGFD). Increlex is marketed in the United States for the treatment of severe Primary IGFD using twice-daily injections.
